USP7 and neoplasm: While further analyses should be performed to better dissect the CK2/USP7/PTEN network, due to the ability of CK2 to activate USP7 as a deubiquitinase and to directly promote PTEN tail phosphorylation, these findings provided the rational for the evaluation of USP7 inhibitor in CLL and therefore we focused on anti-tumor activity of its inhibitor, P5091.